PT  - JOURNAL ARTICLE
AU  - Hannes Treiber
AU  - Alexander Koenig
AU  - Albrecht Neesse
AU  - Annika Richter
AU  - Carsten Oliver Sahlmann
AU  - Arne Strauss
TI  - Liver enzyme elevation after <sup>177</sup>Lu-PSMA radioligand therapy for metastasized castration-resistant prostate cancer
AID  - 10.2967/jnumed.120.258533
DP  - 2021 May 01
TA  - Journal of Nuclear Medicine
PG  - jnumed.120.258533
4099  - http://jnm.snmjournals.org/content/early/2021/05/14/jnumed.120.258533.short
4100  - http://jnm.snmjournals.org/content/early/2021/05/14/jnumed.120.258533.full
AB  - 177Lu-PSMA radioligand therapy (177Lu-PSMA-RLT) is a promising new therapeutic option for patients with metastasized castration-resistant prostate cancer (mCRPC). The spectrum of adverse events with this treatment has to be evaluated. Here, we describe the case of a mCRPC patient with M1c disease (mediastinum, lungs, bones and liver) who presented with elevated liver enzyme levels after 177Lu-PSMA-RLT administration. Pre-treatment 68Ga-PSMA PET/CT showed at least 4 liver lesions with low uptake. Overall, the liver uptake was inhomogeneous. Liver biopsy was performed subsequently.